Status:
COMPLETED
Intravitreal Ketorolac for Chronic Uveitis: A Investigational Safety Study
Lead Sponsor:
Vanderbilt University
Conditions:
Inflammation
Eligibility:
All Genders
18-90 years
Phase:
PHASE1
Brief Summary
Intraocular delivery of ketorolac will be an effective means to treat inflammation and macular edema and prevent structural complications and vision loss in patients with uveitis who are unable to tol...
Detailed Description
A Phase I safety study of intravitreal ketorolac in patients with chronic inflammation and complications due to inflammation who have either failed medical therapy or who cannot tolerate corticosteroi...
Eligibility Criteria
Inclusion
- Adult volunteers
- Chronic intractable uveitis or chronic complications of uveitis (macular edema)despite maximal medical treatment
- Unable to tolerate corticosteroids due to side effects
Exclusion
- 18 years or younger
- Have active ocular infection
- Pregnancy
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01164085
Start Date
December 1 2009
End Date
December 1 2010
Last Update
December 31 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt Eye Institute
Nashville, Tennessee, United States, 37232-8808